Trial results

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

NCT07073417 on ClinicalTrials.gov · last registry update 2026-04-13

Closed to new participants; the 163 already enrolled are still being followed. Due to report 27 February 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Percentage change in body weight relative to baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Hangzhou Sciwind Biosciences Co., Ltd.

Sponsor type

Industry

Enrollment

163

Started

2025-07-28

Primary completion

2027-02-27 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage change in body weight relative to baseline

Conditions studied

Obesity · Weight Management

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.